Related to yesterday’s post, I’m also thrilled to be speaking at a Doing Business in the U.S. program in Derry/Londonderry on the morning (8:30) of September 7, at Invest Northern Ireland’s office there. I’ll also be using the Invest NI office for the balance of the 7th as my ‘office’ in case people need to speak about U.S. expansion. Looking forward to it, and thanks to the great help from @investNI, @investNI_USA, @derry_chamber, and @investdcsdc. Contact Invest NI’s Derry/Londonderry office for more information.
I’m thrilled to announce that I’ll be giving a talk, at the Galway Chamber of Commerce, on September 12 on doing business in the US. I’ll be presenting with Mary Rogers, Innovation Community Manager, PorterShed (@portershed) & Founder & CEO, Stateside Solutions (@StatesidePortal). The program will discuss the following topics: (i) Starting at the start: why expand to the U.S?; (ii) Can your product be sold in the US and/or are there any pre-sale registration or approval requirements?; (iii) Do you need a U.S. affiliate entity? Considerations on form, jurisdiction and tax impact of U.S. affiliate entity; (iv) IP protections; (v) Controlling the contract(s); (vi) Product liability concerns; (vii) Insulating the Irish parent; (viii) Labour/employment/immigration; and (ix) Conclusion: Moving forward. This event will include time for Q&A.
Location: Galway Chamber, Commerce House, Merchant’s Road, Galway Date: Tuesday, 12th September Start Time: 8am Duration: 1 hr 30minutes Price: Free to attend Register here
My partner Montserrat Miller is an expert on workforce compliance issues, including compliance with employment eligibility verification requirements (the I-9 form). She also has her own blog at http://www.workforcecomplianceinsights.com/. Compliance with US employment eligibility verification requirements sometimes slips through the cracks for Irish and NI companies with US employees. It shouldn’t, since the penalties for non-compliance are high. Montserrat can help Irish and NI companies navigate these compliance issues, and she’s compiled a list of resources at http://www.workforcecomplianceinsights.com/2017/07/11/how-compliant-is-your-company-with-the-form-i-9-requirements/. Check out the link, and contact Montserrat (or me) with any questions.
Let’s say you have a lawsuit or an arbitration in Ireland or Northern Ireland and need to obtain evidence in the U.S. How do you do it?
My partner Gene Burd has written an article, recently published on the Young Arbitration Review, on the use of ‘1782’ actions in connection with international arbitrations. 1782 refers to the section of the United States Code that provides a process to obtain evidence in the U.S. for litigation/arbitration outside the U.S. Although Gene’s article focuses on 1782 actions in the arbitration context, the article provides valid insights for litigation. The article can be found here. Feel free to contact Gene (or me) if you have any questions.
Thursday, June 30, 2016 at 3:00 pm Dublin/Belfast.
The attorneys of Arnall Golden Gregory’s International Business Practice invite you to attend a complimentary, 60-minute webinar “What Irish and Northern Irish Companies Need to Know Now: Doing Business in the U.S.” The webinar will be held Thursday, June 30, 2016 at 10:00 am EDT (3:00 pm Dublin/Belfast). The United States is an attractive, and expanding, market for Irish and Northern Irish goods and services. Despite suggestions to the contrary, the U.S. can be an easy market for business expansion—with a little bit of planning. This webinar will examine key legal issues for doing business in the U.S., including:
- Protecting the Irish and Northern Irish parent company, its investors, and capital from U.S. legal risk;
- Avoiding branch profits tax issues;
- Reducing payment risk by ensuring prompt payment from customers, and other U.S. contract essentials;
- The product liability risks that may attach…
View original post 127 more words
The US FDA’s regulation of ‘off-label communications’ (communications about the use of FDA-approved pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration) can be complex and confusing, especially for Irish and Northern Irish life sciences companies marketing/distributing their product in the US. Recent FDA actions have muddied the waters a bit more. Without clear guidance from the FDA , life sciences companies are struggling to decide how best to approach off-label communications, if at all. Continue reading
Bottom line up front: as of last Friday, new changes to the US’s Visa Waiver program restrict the use of that program by persons who have visited Iran, Iraq, Syria, or the Sudan at any time after March 1, 2011. Additional “countries of concern” may be added to this list. The nationality of the traveler is not an issue, so this change impacts any person traveling on an Irish or UK passport who has been to the listed countries in the relevant timeframe. Continue reading